Current status of therapeutic drug monitoring in Australia and New Zealand: A need for improved assay evaluation, best practice guidelines, and professional development

Therapeutic Drug Monitoring

Volumn 32, Issue 5, 2010, Pages 615-623

  Norris, Ross L ^a,b,i   Martin, Jennifer H ^c,i   Thompson, Erin ^c,i   Ray, John E ^d   Fullinfaw, Robert O ^e   Joyce, David ^f,j   Barras, Michael ⁱ   Jones, Graham R ^d   Morris, Raymond G ^g,h  

^a MATER HOSPITAL   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g QUEEN ELIZABETH HOSPITAL   (Australia)

^h UNIVERSITY OF ADELAIDE   (Australia)

ⁱ UNIVERSITY OF QUEENSLAND   (Australia)

^j PATHWEST LABORATORY MEDICINE   (Australia)

more..

Author keywords

Australia; New Zealand; survey; therapeutic drug monitoring

Indexed keywords

ALCOHOL; AMIKACIN; AMIODARONE; AMITRIPTYLINE; CARBAMAZEPINE; CYCLOSPORIN; DIGOXIN; DISOPYRAMIDE; ETHOSUXIMIDE; GENTAMICIN; LIDOCAINE; LITHIUM; METHOTREXATE; MYCOPHENOLIC ACID; NETILMICIN; NORTRIPTYLINE; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; QUINIDINE; RAPAMYCIN; SALICYLIC ACID; TACROLIMUS; THEOPHYLLINE; TOBRAMYCIN; VALPROIC ACID; VANCOMYCIN;

ADULT; AFFINITY COLUMN MEDIATED IMMUNOASSAY; ALCOHOL BLOOD LEVEL; ARTICLE; ASSAY; AUSTRALIA; CHEMOLUMINESCENCE; CHILD; CLINICAL LABORATORY; CLINICAL PRACTICE; CLONED ENZYME DONOR IMMUNOASSAY; COLORIMETRY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG MONITORING; ELECTROCHEMICAL ANALYSIS; ELECTROCHEMICAL LUMINESENCE; ENZYMATIC HETEROGENOUS COMPETITION IMMUNOASSAY; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FLAME PHOTOMETRY; FLUORESCENCE POLARIZATION; FLUORESCENCE POLARIZATION IMMUNOASSAY; FLUOROMETRY; GAS CHROMATOGRAPHY; GOOD LABORATORY PRACTICE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; METHODOLOGY; MICROPARTICLE ENZYME IMMUNOASSAY; NEW ZEALAND; NEWBORN; PARTICLE ENHANCED TURBIDIMETRIC INHIBITION IMMUNOASSAY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL DEVELOPMENT; QUESTIONNAIRE; TANDEM MASS SPECTROMETRY;

AUSTRALIA; BENCHMARKING; DRUG MONITORING; NEW ZEALAND; PHARMACY SERVICE, HOSPITAL; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES;

EID: 77957253366     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181ea3e8a     Document Type: Article

References (26)

1. Public Health Expenditure in Australia 2007-2008. Available at: http:// www.aihw.gov.au/publications/hwe/hwe-47-10952/hwe-47-10952.pdf. Accessed December 4, 2009.
2. Australian Government Treasury, Appendix A. Spending Projections. Available at: http://www.treasury.gov.au/documents/1239/HTML/docshell. asp?URL=06-Appendix-A.htm. Accessed December 4, 2009.
3. Joyce C, McNeil J, Stoelwinder J. More doctors, but not enough: Australian medical workforce supply 2001-2012. Med J Aust. 2006; 184:441-446.
4. Australian Bureau of Statistics. 3222.0 Population Projections-Australia 2006-2101. Available at: http://www.abs.gov.au/ausstats/absatnsf/mf/ 3222.0. Accessed December 4, 2009.
5. Roughead E, Semple S. Medication safety in acute care in Australia: where are we now? Part I: a review of the extent and causes of medication problems 2002-2008. Aust NZ Health Policy. 2009;6:18.
6. Runciman W, Roughead E, Semple SJ, et al. Adverse drug events and medication errors in Australia. Int J Qual Health Care. 2003;15(Suppl 1): 49-59.
7. Budnitz D, Shehab N, Kegler SR, et al. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med. 2007;147:755-765.
8. van Lent-Evers N, Mathot R, Geus W, et al. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit. 1999; 21:63-73.
9. Gardiner S, Begg E. Pharmacogenetic testing for drug metabolising enzymes: is it happening in practice? Pharmacogenet Genomics. 2005; 15:365-369.
10. Available at: www.rcpaqap.com.au. Accessed February 23, 2010.
11. Morris RG. Australian cyclosporin therapeutic monitoring method survey: 1993. Ther Drug Monit 1994;16:564-569.
12. Morris R, Lam A. Cyclosporin monitoring in Australasia: survey of laboratory practices in 2000. Ther Drug Monit. 2002;24:471-478.
13. Jones T, Morris R. Survey of cyclosporine therapeutic ranges, assay methodology, and use of 'sparing agents' in Australasian transplant centers. Ther Drug Monit. 1997;19:650-656.
14. Jones G. Reporting units for therapeutic drug monitoring: a correctable source of potential clinical error. Med J Aust. 2007;186:420-421.
15. Morris R, Tett S, Ray J. Cyclosporin A monitoring in Australia: consensus recommendations. Ther Drug Monit. 1994;16:570-576.
16. Morris R, Ilett K, Tett S, et al. Cyclosporin monitoring in Australasia: 2002 update of consensus guidelines. Ther Drug Monit. 2002;24: 677-688.
17. Rogers NM, Jones TE, Morris RG. Frequently discordant results from therapeutic drug monitoring for digoxin-clinical confusion. Int Med J. 2010;40:52-56.
18. Dasgupta A, Kang E, Datta P. A new enzyme-linked chemiluminescent immunosorbent digoxin assay is virtually free from interference of spironolactone, potassium canrenoate and their common metabolite canrenone. J Clin Lab Anal. 2006;20:204-208.
19. Steimer W, Muller C, Eber B. Digoxin assay: frequent, substantial and potentially dangerous interference by spironolactone, canrenone, and other steroids. Clin Chem. 2002;48:507-516.
20. International Proficiency Testing Schemes for Ciclosporin. Available at: www.bioanalytics.co.uk. Accessed December 16, 2009.
21. Joint Committee on Traceability in Laboratory Medicine. Available at: www.bipm.org/jctlm/. Accessed December 12, 2009.
22. Rybak M, Lomaestro B, Rotschafer J, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82-98.
23. Therapeutic Guidelines (eTG). Melbourne, Australia. Available at: http:// www.tg.org.au/?sectionid=41. Accessed December 4, 2009.
24. Touw D, Neef C, Thomson A, et al. Cost-effectiveness of therapeutic drug monitoring. A systematic review. Ther Drug Monit. 2005;27:10-17.
25. Gunten V, Reymond J-P, Beney J. Clinical and economic outcomes of pharmaceutical services related to antibiotic use: a literature review. Pharm World Sci. 2007;29:146-163.
26. Walko C, McLeod H. Will we ever be ready for blood level-guided therapy? J Clin Oncol. 2008;26:2078-2079.